Anavex Life Sciences Corp. (NASDAQ: AVXL) reported its third quarter fiscal 2025 financial results and provided an update on its ongoing clinical developments on August 12, 2025. The company focuses on advancing treatments for central nervous system disorders like Alzheimer's disease, Parkinson's disease, and Rett syndrome. According to CEO Christopher U. Missling, the progress in developing oral, non-invasive therapies underscores the demand for effective treatment options, especially for Alzheimer's patients. Significant findings regarding the oral small molecule blarcamesine were presented during the Alzheimer's Association International Conference (AAIC) 2025, highlighting its prolonged benefits over four years in early-stage Alzheimer's patients. Financially, Anavex reported cash and cash equivalents of $101.2 million as of June 30, 2025, down from $132.2 million at the end of fiscal 2024.